Literature DB >> 17916981

APS--more systemic disease than SLE.

Yehuda Shoenfeld1.   

Abstract

The antiphospholipid syndrome is a systemic autoimmune disease that can have serious consequences for patients. Importantly, there is a wide range of clinical presentations. In this issue we have attempted to provide an overview of these features and place it in the context of autoimmunity.

Entities:  

Mesh：

Year:  2007        PMID： 17916981     DOI： 10.1007/s12016-007-0005-z

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


  20 in total

1.  Systemic antiphospholipid syndrome.

Authors:  Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

Review 2.  Orthopaedic manifestations of the antiphospholipid (Hughes) syndrome.

Authors:  S Vasoo; S Sangle; M Zain; D D'Cruz; G Hughes
Journal:  Lupus       Date:  2005       Impact factor: 2.911

Review 3.  The systemic nature of the antiphospholipid syndrome.

Authors:  I Marai; G Zandman-Goddard; Y Shoenfeld
Journal:  Scand J Rheumatol       Date:  2004       Impact factor: 3.641

4.  Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome.

Authors:  Marisol Languren; Baltazar Becerril; Antonio R Cabral; Luisa E Fernández-Altuna; Virginia Pascual; Diego F Hernández-Ramírez; Javier Cabiedes
Journal:  J Autoimmun       Date:  2005-12-05       Impact factor: 7.094

Review 5.  Antiphospholipid antibodies: lessons from the bench.

Authors:  Takao Koike; Miyuki Bohgaki; Olga Amengual; Tatsuya Atsumi
Journal:  J Autoimmun       Date:  2007-03-23       Impact factor: 7.094

Review 6.  New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS").

Authors:  Ronald A Asherson
Journal:  Autoimmun Rev       Date:  2006-07-17       Impact factor: 9.754

7.  Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI.

Authors:  G Michael Iverson; Carlos A von Mühlen; Henrique L Staub; Andrew J Lassen; Walter Binder; Gary L Norman
Journal:  J Autoimmun       Date:  2006-10-31       Impact factor: 7.094

Review 8.  The management of the patient with unexpected autoantibody positivity.

Authors:  Marcello Bagnasco; Lidia Grassia; Giampaola Pesce
Journal:  Autoimmun Rev       Date:  2007-02-15       Impact factor: 9.754

Review 9.  Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?

Authors:  Ilaria Cavazzana; Nebuloni Manuela; Cetin Irene; Acaia Barbara; Saino Sara; Borghi Maria Orietta; Tincani Angela; Tedesco Francesco; Meroni Pier Luigi
Journal:  J Autoimmun       Date:  2007-04-06       Impact factor: 7.094

10.  Pharmacogenomics and its implications for autoimmune disease.

Authors:  Colin J D Ross; Hagit Katzov; Bruce Carleton; Michael R Hayden
Journal:  J Autoimmun       Date:  2007-04-05       Impact factor: 7.094
View more
  4 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

3.  Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.

Authors:  Entela Nuri; Mara Taraborelli; Laura Andreoli; Marta Tonello; Maria Gerosa; Antonia Calligaro; Lorenza Maria Argolini; Rajesh Kumar; Vittorio Pengo; Pier Luigi Meroni; Amelia Ruffatti; Angela Tincani
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Bouquet variety of antiphospholipid antibodies in recurrent pregnancy loss.

Authors:  Marta P Baleva; Zhivka P Karagyozova; Milena K Nikolova-Vlahova; Krasimir V Nikolov; Petar K Nikolov
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.